Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 25 Sep 2026 · Editorial standards

At a glance

Lenvatinib is named as an intervention in 94 current clinical trials in our China, USA, UK, Ireland and India registers. 50 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Merck Sharp & Dohme LLC (11). The most-studied condition is Hepatocellular Carcinoma.

Lenvatinib also has an approved-drug profile on this site (FDA label data): Lenvima (Lenvatinib) →

Trials by status

Recruiting5053%
Not yet open1819%
Active, closed2527%
By invitation11%

Trials by phase

Phase 24649%
Phase 31819%
Phase 1/21213%
Not applicable77%
Phase 144%
Phase 433%
Observational22%
Phase EARLY_PHASE111%
Phase 2/311%

Clinical trials of Lenvatinib

94 trials

Study	Phase	Status	Lead sponsor	Registers
Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC. NCT06311942 · ClinicalTrials.gov ↗ · HCC	Phase 4	Recruiting	Chen Xiaoping	China
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) NCT03486873 · Solid Tumors, Hematologic Malignancies	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study NCT05342194 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma	Phase 3	Recruiting	Shanghai Junshi Bioscience Co., Ltd.	China
Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC NCT05608200 · Hepatocellular Carcinoma Non-resectable	Phase 3	Recruiting	Second Affiliated Hospital of Guangzhou Medical University	China
Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC NCT05608213 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Non-resectable	Phase 3	Recruiting	Second Affiliated Hospital of Guangzhou Medical University	China
FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial NCT06201065 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 3	Recruiting	Sun Yat-sen University	China
A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma NCT06371157 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 3	Recruiting	Akeso	China
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) NCT07405164 · ClinicalTrials.gov ↗ · Von Hippel-Lindau Disease, Malignant Neoplasms	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA
A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence NCT07475026 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma	Phase 3	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma NCT05057845 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma	Phase 2	Recruiting	Fudan University	China
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial NCT05327686 · ClinicalTrials.gov ↗ · Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8	Phase 2	Recruiting	NRG Oncology	Ireland
Lenvatinib for Advanced Bone and Soft Tissue Sarcoma NCT05617859 · ClinicalTrials.gov ↗ · Effectiveness, Sexuality	Phase 2	Recruiting	Henan Cancer Hospital	China
Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11) NCT06032845 · ClinicalTrials.gov ↗ · Solid Tumor, Adult	Phase 2	Recruiting	Fudan University	China
HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma NCT06187961 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Non-resectable	Phase 2	Recruiting	Tongji Hospital	China
Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma NCT06192797 · ClinicalTrials.gov ↗ · Cholangiocarcinoma Non-resectable	Phase 2	Recruiting	Tongji Hospital	China
Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors NCT06208462 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401) NCT06261125 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2	Recruiting	Mian XI	China
Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma NCT06406634 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2	Recruiting	Hunan Cancer Hospital	China
Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model NCT06420440 · HCC	Phase 2	Recruiting	Chen Xiaoping	China
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer NCT06482086 · ClinicalTrials.gov ↗ · Locally Advanced Thyroid Gland Carcinoma	Phase 2	Recruiting	West China Hospital	China
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion NCT06739395 · ClinicalTrials.gov ↗ · Solid Tumor, Precision Medicine	Phase 2	Recruiting	Tianjin Medical University Second Hospital	China
Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01) NCT06860477 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocellular Carcinoma	Phase 2	Recruiting	Fudan University	China
Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC NCT06904014 · ClinicalTrials.gov ↗ · HCC	Phase 2	Recruiting	Lei ZHAO	China
A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer NCT06962787 · ClinicalTrials.gov ↗ · Renal Cancer	Phase 2	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd.	China
Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma NCT07014150 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Resectable	Phase 2	Recruiting	Peking Union Medical College Hospital	China
Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab NCT07047586 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Phase 2	Recruiting	Fudan University	China
QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer NCT07110064 · ClinicalTrials.gov ↗ · Advance Pancreatic Cancer	Phase 2	Recruiting	Du Juan	China
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC NCT07157969 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma	Phase 2	Recruiting	Peking Union Medical College Hospital	China
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure NCT07219459 · ClinicalTrials.gov ↗ · Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound	Phase 2	Recruiting	CatalYm GmbH	UK, USA
An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy. NCT07282262 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 2	Recruiting	Peking Union Medical College Hospital	China
A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma NCT07328009 · ClinicalTrials.gov ↗ · Hepato Cellular Carcinoma (HCC)	Phase 2	Recruiting	Fudan University	China
MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced Sarcoma NCT07359053 · ClinicalTrials.gov ↗ · Sarcoma	Phase 2	Recruiting	Shanghai 6th People's Hospital	China
QL1706 Plus Lenvatinib in Previously Treated Penile Cancer NCT07384416 · ClinicalTrials.gov ↗ · Penile Cancer	Phase 2	Recruiting	Sun Yat-sen University	China
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC NCT07389629 · ClinicalTrials.gov ↗ · Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy	Phase 2	Recruiting	Sun Yat-sen University	China
Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma NCT07571551 · ClinicalTrials.gov ↗ · Clear Cell RCC	Phase 2	Recruiting	Jinling Hospital, China	China
Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer NCT07670273 · ClinicalTrials.gov ↗ · Biliary Tract Neoplasms Immunotherapy	Phase 2	Recruiting	Peking Union Medical College Hospital	China
Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer NCT07704177 · ClinicalTrials.gov ↗ · Biliary Tract Neoplasms Immunotherapy	Phase 2	Recruiting	Peking Union Medical College Hospital	China
Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus NCT07776080 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma	Phase 2	Recruiting	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types NCT04300556 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1/2	Recruiting	Eisai Inc.	UK, USA
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors NCT04977453 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer	Phase 1/2	Recruiting	GI Innovation, Inc.	USA
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors NCT05024214 · ClinicalTrials.gov ↗ · Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma	Phase 1/2	Recruiting	3D Medicines (Sichuan) Co., Ltd.	China
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) NCT05319730 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA, China
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma NCT05797805 · Advanced Hepatocellular Carcinoma	Phase 1/2	Recruiting	Iterion Therapeutics	USA
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours NCT06682780 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1/2	Recruiting	LaNova Medicines Limited	China
Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma NCT07097935 · ClinicalTrials.gov ↗ · Advanced Clear Cell Renal Cell Carcinoma	Phase 1/2	Recruiting	Jiangsu Hansoh Pharmaceutical Co., Ltd.	China
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) NCT06858813 · ClinicalTrials.gov ↗ · Hepatocellular Cancer, Squamous-Cell Non-Small Cell Lung Cancer	Phase 1	Recruiting	AbbVie	USA, China
HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC NCT06632093 · ClinicalTrials.gov ↗ · BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy	Observational	Recruiting	First Hospital of China Medical University	China
bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC NCT06061276 · ClinicalTrials.gov ↗ · Liver Diseases, Hepatocellular Carcinoma, Immunotherapy	Not applicable	Recruiting	Sun Yat-sen University	China
TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT NCT06622031 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Systemic Therapy	Not applicable	Recruiting	Sun Yat-sen University	China
TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma NCT06740370 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization, Anti-PD1 Antibody	Not applicable	Recruiting	Sun Yat-sen University	China
Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study NCT07010393 · ClinicalTrials.gov ↗ · Thyroid Neoplasms	Phase 4	Not yet open	Fujian Medical University	China
A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular Invasion NCT07790419 · ClinicalTrials.gov ↗ · Liver Cancer	Phase 4	Not yet open	Zhai Wenlong	China
SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH) NCT05718232 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma	Phase 3	Not yet open	Sun Yat-sen University	China
A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection NCT06089382 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 3	Not yet open	Tongji Hospital	China
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma NCT07691515 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma (Icc)	Phase 3	Not yet open	Zhejiang Cancer Hospital	China
Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer NCT07177716 · ClinicalTrials.gov ↗ · Cervical Cancer	Phase 2/3	Not yet open	L & L Bio Co., Ltd., Ningbo, China	China
Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma NCT04622566 · ClinicalTrials.gov ↗ · Mucosal Melanoma, Neoadjuvant Treatment	Phase 2	Not yet open	Peking University Cancer Hospital & Institute	China
Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC NCT06648525 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma (Icc)	Phase 2	Not yet open	Harbin Medical University	China
Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06) NCT06919848 · ClinicalTrials.gov ↗ · Biliary Tract Cancer (BTC)	Phase 2	Not yet open	Fudan University	China
A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma NCT07131501 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Immunotherapy, Preoperative	Phase 2	Not yet open	The First Affiliated Hospital with Nanjing Medical University	China
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer NCT07159217 · ClinicalTrials.gov ↗ · Biliary Tract Cancer, Disitamab Vedotin, Lenvatinib	Phase 2	Not yet open	Peking Union Medical College Hospital	China
Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification NCT07417501 · ClinicalTrials.gov ↗ · Solid Tumors	Phase 2	Not yet open	Tongji Hospital	China
Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial NCT07715565 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma (Kidney Cancer), Immunotherapy, Molecular Targeted Therapy	Phase 2	Not yet open	West China Hospital	China
A Prospective, Single-Arm, Multicenter Clinical Study of High-Risk Localized and Locally Advanced Renal Clear Cell Carcinoma NCT07741617 · ClinicalTrials.gov ↗ · Urologic Neoplasms	Phase 2	Not yet open	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	China
Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer. NCT07829874 · ClinicalTrials.gov ↗ · Biliary Tract Cancer (BTC)	Phase 2	Not yet open	Fudan University	China
FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation NCT06409637 · ClinicalTrials.gov ↗ · Liver Cancer, Liver Transplant	Phase 1/2	Not yet open	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma NCT06463548 · ClinicalTrials.gov ↗ · Biliary Tract Carcinoma	Not applicable	Not yet open	Yunpeng Liu	China
Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC NCT07480382 · ClinicalTrials.gov ↗ · Initially Unresectable Hepatocellular Carcinoma	Not applicable	Not yet open	Hong Wu	China
Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma NCT07356466 · ClinicalTrials.gov ↗ · Gastric (Stomach) Cancer	Phase EARLY_PHASE1	By invitation	Fujian Medical University	China
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma NCT02811861 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma	Phase 3	Active, closed	Eisai Inc.	Ireland, UK, USA
A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma NCT04194775 · Hepatocellular Carcinoma	Phase 3	Active, closed	CStone Pharmaceuticals	USA, China
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) NCT04586231 · Carcinoma, Renal Cell	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) NCT04736706 · ClinicalTrials.gov ↗ · Carcinoma, Renal Cell	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab NCT04770896 · ClinicalTrials.gov ↗ · Unresectable Hepatocellular Carcinoma	Phase 3	Active, closed	Hoffmann-La Roche	UK, China
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC NCT05301842 · Hepatocellular Carcinoma	Phase 3	Active, closed	AstraZeneca	USA, India, China
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study NCT05899049 · ClinicalTrials.gov ↗ · Carcinoma, Renal Cell	Phase 3	Active, closed	Merck Sharp & Dohme LLC	China
Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) NCT04976634 · ClinicalTrials.gov ↗ · Neoplasm Malignant	Phase 2	Active, closed	Merck Sharp & Dohme LLC	USA
A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients NCT05078931 · ClinicalTrials.gov ↗ · NSCLC	Phase 2	Active, closed	Shanghai Chest Hospital	China
A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC NCT05319431 · ClinicalTrials.gov ↗ · Unresectable, Non-metastatic Hepatocellular Carcinoma	Phase 2	Active, closed	Akeso	China
Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy NCT05585580 · ClinicalTrials.gov ↗ · Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 2	Active, closed	Qilu Hospital of Shandong University	China
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer NCT05775159 · Hepatocellular Carcinoma, Biliary Tract Cancer	Phase 2	Active, closed	AstraZeneca	UK, USA, China
Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) NCT05822752 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2	Active, closed	AbbVie	USA, China
Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer NCT05824468 · ClinicalTrials.gov ↗ · Cervical Cancer, Cervical Carcinoma	Phase 2	Active, closed	Sun Yat-sen University	China
Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer NCT05824481 · ClinicalTrials.gov ↗ · Endometrial Cancer, Endometrial Adenocarcinoma	Phase 2	Active, closed	Sun Yat-sen University	China
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor NCT04008797 · ClinicalTrials.gov ↗ · Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular	Phase 1/2	Active, closed	Eisai Inc.	USA, China
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) NCT04626479 · ClinicalTrials.gov ↗ · Carcinoma, Renal Cell	Phase 1/2	Active, closed	Merck Sharp & Dohme LLC	UK, USA
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) NCT04626518 · ClinicalTrials.gov ↗ · Carcinoma, Renal Cell	Phase 1/2	Active, closed	Merck Sharp & Dohme LLC	UK, USA
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) NCT04938817 · ClinicalTrials.gov ↗ · Small Cell Lung Carcinoma	Phase 1/2	Active, closed	Merck Sharp & Dohme LLC	USA
A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma NCT04522323 · ClinicalTrials.gov ↗ · Advanced Renal Cell Carcinoma	Phase 1	Active, closed	MedImmune LLC	USA
A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010) NCT05030506 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma	Phase 1	Active, closed	Merck Sharp & Dohme LLC	China
Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC) NCT06462183 · ClinicalTrials.gov ↗ · Adenoid Cystic Carcinoma, Colorectal Cancer	Phase 1	Active, closed	Rgenta Therapeutics Inc	USA
HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion NCT07466225 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Observational	Active, closed	Peking University	China
HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma NCT05621499 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Not applicable	Active, closed	Tianjin Medical University Cancer Institute and Hospital	China
Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCC NCT06519721 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Not applicable	Active, closed	RenJi Hospital	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Lenvatinib

93 conditions

Hepatocellular Carcinoma16Carcinoma, Renal Cell5Solid Tumors3Renal Cell Carcinoma3Biliary Tract Cancer3Advanced Hepatocellular Carcinoma3Cervical Cancer3HCC3Hepatocellular Carcinoma Non-resectable3Lenvatinib3Immunotherapy3HCC - Hepatocellular Carcinoma3

All 93 conditions

Condition (as registered)	Trials
Hepatocellular Carcinoma	16
Carcinoma, Renal Cell	5
Solid Tumors	3
Renal Cell Carcinoma	3
Biliary Tract Cancer	3
Advanced Hepatocellular Carcinoma	3
Cervical Cancer	3
HCC	3
Hepatocellular Carcinoma Non-resectable	3
Lenvatinib	3
Immunotherapy	3
HCC - Hepatocellular Carcinoma	3
Solid Tumor	2
Advanced Solid Tumor	2
Hepatocellular Carcinoma (HCC)	2
Liver Cancer	2
Biliary Tract Neoplasms Immunotherapy	2
Biliary Tract Cancer (BTC)	2
Intrahepatic Cholangiocarcinoma (Icc)	2
Intrahepatic Cholangiocarcinoma	2
Hematologic Malignancies	1
Metastatic Renal Cell Carcinoma	1
Stage III Renal Cell Cancer AJCC v8	1
Stage IV Renal Cell Cancer AJCC v8	1
Unresectable Renal Cell Carcinoma	1
Von Hippel-Lindau Disease	1
Malignant Neoplasms	1
Unresectable or Metastatic Hepatocellular Carcinoma	1
Child-Pugh A Hepatocellular Carcinoma	1
Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound	1
Unresectable Hepatocellular Carcinoma	1
Advanced Renal Cell Carcinoma	1
Small Cell Lung Carcinoma	1
Endometrial Neoplasms	1
Neoplasms	1
Carcinoma, Hepatocellular	1
Liver Neoplasms	1
Adenoid Cystic Carcinoma	1
Colorectal Cancer	1
Hepatocellular Cancer	1
Squamous-Cell Non-Small Cell Lung Cancer	1
Esophageal Squamous Cell Carcinoma	1
Neoplasm Malignant	1
Metastatic Solid Tumor	1
Urothelial Carcinoma	1
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	1
Liver Transplant	1
Hepato Cellular Carcinoma (HCC)	1
Cervical Carcinoma	1
Advanced Clear Cell Renal Cell Carcinoma	1
Disitamab Vedotin	1
Immune Checkpoint Inhibitors	1
Portal Vein Tumor Thrombus	1
Systemic Therapy	1
Hepatocellular Carcinoma Resectable	1
Preoperative	1
PD-1	1
Gastric (Stomach) Cancer	1
BCLC Stage B Hepatocellular Carcinoma	1
BCLC Stage C Hepatocellular Carcinoma	1
Hepatic Arterial Infusion Chemotherapy	1
Biliary Tract Carcinoma	1
Transcatheter Arterial Chemoembolization	1
Anti-PD1 Antibody	1
Precision Medicine	1
Liver Diseases	1
Camrelizumab	1
Penile Cancer	1
Non-small Cell Lung Cancer	1
Solid Tumor, Adult	1
Iparomlimab and Tuvonralimab	1
Clear Cell Renal Cell Carcinoma	1
Neoadjuvant Therapy	1
Renal Cell Carcinoma (Kidney Cancer)	1
Molecular Targeted Therapy	1
Advance Pancreatic Cancer	1
Unresectable, Non-metastatic Hepatocellular Carcinoma	1
Thyroid Neoplasms	1
Sarcoma	1
Clear Cell RCC	1
Initially Unresectable Hepatocellular Carcinoma	1
Renal Cancer	1
Cholangiocarcinoma Non-resectable	1
NSCLC	1
Locally Advanced Thyroid Gland Carcinoma	1
Urologic Neoplasms	1
Endometrial Cancer	1
Endometrial Adenocarcinoma	1
Intrahepatic Cholangiocellular Carcinoma	1
Mucosal Melanoma	1
Neoadjuvant Treatment	1
Effectiveness	1
Sexuality	1

By country register

Register	Trials	Recruiting
Clinical trials in China	80	44
Clinical trials in USA	22	8
Clinical trials in UK	11	4
Clinical trials in Ireland	5	2
Clinical trials in India	1	0

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Lenvatinib trials

How many clinical trials are testing Lenvatinib?

94 current trials in our China, USA, UK, Ireland and India registers name Lenvatinib (also registered as MK-7902) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.

Are Lenvatinib trials recruiting patients?

Yes. 50 of the 94 trials are recruiting: 44 with sites in China, 8 with sites in USA, 4 with sites in UK and 2 with sites in Ireland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Lenvatinib clinical trials?

Merck Sharp & Dohme LLC (11), Sun Yat-sen University (9), Fudan University (7) and Peking Union Medical College Hospital (6), among 51 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Lenvatinib works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Lenvatinib works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Lenvatinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Lenvatinib clinical trials